Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral edaravone extension study in ALS after MT-1186-A02
2021-003900-42Phase 3Terminated
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Continuous oral edaravone with On/off oral edaravone regimen including placebo (2 arms). Primary endpoint: Time to 12-point ALSFRS-R decrease or death. Started Mar 2022; status: terminated.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2021-003900-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003900-42.